
Authors reply:

**Platelet inhibitors influence cardioprotection: importance in preclinical study design**

Sandrine Lecour  
Associate Professor in the Department of Medicine  
Hatter Institute for Cardiovascular Research in Africa and MRC Inter-University Cape Heart Group  
University of Cape Town, South Africa

Rainer Schulz  
Professor of Physiology  
Institute of Physiology  
Justus-Liebig University, Giessen, Germany

Péter Ferdinandy  
Professor of Pharmacology and Clinical Pharmacology  
Department of Pharmacology and Pharmacotherapy, Semmelwies University, Budapest, Hungary  
Pharmahungary Group, Szeged, Hungary

Derek J Hausenloy  
Professor of Cardiovascular Medicine  
The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, UK; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, UK; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore.
We would like to thank Professors Cohen and Downey for highlighting platelet inhibitors, in particular platelet P2Y12 receptor antagonists, as an important confounder to take into consideration in preclinical studies designed to study novel cardioprotective strategies against ischemia/reperfusion injury. As already mentioned in our recent publication from the ESC working group, both clinical and animal studies give evidence that platelet inhibitors reduce myocardial infarct size by mechanisms that may involve nitric oxide or adenosine.1-3 Over the past few years, Cohen and Downey have published strong and convincing evidence suggesting that additional protection cannot be afforded with pharmacological and/or mechanical protective strategies sharing the same pro-survival signaling pathways as the P2Y12 antagonist (see review3). Therefore, we fully share their point of view that the effect of co-medication with P2Y12 antagonists or with any other medications frequently given to ischemic heart disease patients (e.g. aspirin, statins, ACE inhibitors, beta blockers, etc)1 on cardioprotective therapies needs to be tested in preclinical settings prior to translation to clinical cardioprotection as also recently reviewed in detail by Ferdinandy et al.4


